Midterm Results of High-Dose-Rate Intraoperative Brachytherapy in the Treatment of Soft Tissue Sarcomas

Author:

Dammerer Dietmar123ORCID,Neugebauer Johannes123,Braito Matthias4,Wagner Moritz4ORCID,Neubauer Markus1ORCID,Moser Lukas1,Süß Markus2,Liebensteiner Michael2,Putzer David5ORCID

Affiliation:

1. Department of Orthopaedics and Traumatology, University Hospital Krems, 3500 Krems, Austria

2. Department of Orthopaedics and Traumatology, Medical University of Innsbruck, 6020 Innsbruck, Austria

3. Karl Landsteiner Private University for Health Sciences, 3500 Krems, Austria

4. Department of Orthopaedics and Traumatology, St. Johann in Tirol Hospital, 6380 St. Johann in Tirol, Austria

5. Department of Experimental Orthopaedics, Medical University of Innsbruck, 6020 Innsbruck, Austria

Abstract

Introduction: According to the literature only sparse data are available on the use of high-dose-rate intraoperative brachytherapy (IOHDR-BT) as a boost to external-beam irradiation (EBRT) in combination with a wide resection in patients with high-grade soft tissue sarcomas (STS). Materials and Methods: Applying a retrospective study design, we investigated all patients who between 2010 and 2016 underwent marginal resection of a high-grade STS and intraoperative radiotherapy, followed by EBRT. We included only patients with a traceable follow-up time of at least two years. Of 89 patients, 35 met our inclusion criteria and showed an average follow-up of four years. Results: We found an overall 2-year local control rate of 94.3%. The local recurrence rate for R0 resections was 6%, whereas recurrences occurred in 13% of R1 resections and in 100% of R2 resections. One affected patient received only intraoperative radiotherapy. The recurrence rate by tumour entity was 36% for LPS, 11% for myxofibrosarcoma and 17% for undifferentiated pleomorphic sarcoma. Conclusion: The treatment regimen consisting of limb-preserving surgery, IORT and pre- or postoperative radiotherapy consistently shows excellent local control rates.

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference55 articles.

1. The Epidemiology of Sarcoma;Burningham;Clin. Sarcoma Res.,2012

2. (2022, June 11). SEER Cancer Statistics Review, 1975–2017. SEER, Available online: https://seer.cancer.gov/csr/1975_2017/index.html.

3. Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project;Stiller;Eur. J. Cancer,2013

4. Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review;Wibmer;Ann. Oncol.,2010

5. Brodowicz, T., Amann, G., Leithner, A., Sztankay, A., Kainberger, F., Eisterer, W., Liegl-Atzwanger, B., Rachbauer, F., Rath, T., and Bergmann, M. (2022, June 11). Diagnose und Therapie von Weichteilsarkomen (interdisziplinär). Comprehensive Cancer Center Standard Operating Procedure; Version 3; 2017. Available online: https://www.ccc.ac.at/fileadmin/ccc/SOPs/CCC_SOP_Diagnose_und_Therapie_von_Weichteilsarkomen_interdisz_03_17.pdf.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3